These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 266212)

  • 1. 5'-deoxypyridoxal as a potential anti-sickling agent.
    Benesch R; Benesch RE; Edalji R; Suzuki T
    Proc Natl Acad Sci U S A; 1977 Apr; 74(4):1721-3. PubMed ID: 266212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of erythrocyte sickling in vitro by pyridoxal.
    Kark JA; Kale MP; Tarassoff PG; Woods M; Lessin LS
    J Clin Invest; 1978 Oct; 62(4):888-91. PubMed ID: 701485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Substituted benzaldehydes designed to increase the oxygen affinity of human haemoglobin and inhibit the sickling of sickle erythrocytes.
    Beddell CR; Goodford PJ; Kneen G; White RD; Wilkinson S; Wootton R
    Br J Pharmacol; 1984 Jun; 82(2):397-407. PubMed ID: 6733364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pyridoxal phosphate as an antisickling agent in vitro.
    Kark JA; Tarassoff PG; Bongiovanni R
    J Clin Invest; 1983 May; 71(5):1224-9. PubMed ID: 6853710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of 2-imidazolines as anti-sickling agents.
    Chang H; Ewert SM; Nagel RL
    Mol Pharmacol; 1983 May; 23(3):731-4. PubMed ID: 6865916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New developments in anti-sickling agents: can drugs directly prevent the polymerization of sickle haemoglobin in vivo?
    Oder E; Safo MK; Abdulmalik O; Kato GJ
    Br J Haematol; 2016 Oct; 175(1):24-30. PubMed ID: 27605087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of sickle cell disease by increasing oxygen affinity of hemoglobin.
    Henry ER; Metaferia B; Li Q; Harper J; Best RB; Glass KE; Cellmer T; Dunkelberger EB; Conrey A; Thein SL; Bunn HF; Eaton WA
    Blood; 2021 Sep; 138(13):1172-1181. PubMed ID: 34197597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of carbon dioxide and pH variations in vitro on blood respiratory functions, red blood cell volume, transmembrane pH gradients, and sickling in sickle cell anemia.
    Ueda Y; Bookchin RM
    J Lab Clin Med; 1984 Aug; 104(2):146-59. PubMed ID: 6431043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease.
    Oksenberg D; Dufu K; Patel MP; Chuang C; Li Z; Xu Q; Silva-Garcia A; Zhou C; Hutchaleelaha A; Patskovska L; Patskovsky Y; Almo SC; Sinha U; Metcalf BW; Archer DR
    Br J Haematol; 2016 Oct; 175(1):141-53. PubMed ID: 27378309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Triazole Disulfide Compound Increases the Affinity of Hemoglobin for Oxygen and Reduces the Sickling of Human Sickle Cells.
    Nakagawa A; Ferrari M; Schleifer G; Cooper MK; Liu C; Yu B; Berra L; Klings ES; Safo RS; Chen Q; Musayev FN; Safo MK; Abdulmalik O; Bloch DB; Zapol WM
    Mol Pharm; 2018 May; 15(5):1954-1963. PubMed ID: 29634905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative evaluation of fifteen anti-sickling agents.
    Chang H; Ewert SM; Bookchin RM; Nagel RL
    Blood; 1983 Apr; 61(4):693-704. PubMed ID: 6338971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Schiff base adducts of hemoglobin. Modifications that inhibit erythrocyte sickling.
    Zaugg RH; Walder JA; Klotz IM
    J Biol Chem; 1977 Dec; 252(23):8542-8. PubMed ID: 925011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic strategies to alter the oxygen affinity of sickle hemoglobin.
    Safo MK; Kato GJ
    Hematol Oncol Clin North Am; 2014 Apr; 28(2):217-31. PubMed ID: 24589263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative prediction of erythrocyte sickling for the development of advanced sickle cell therapies.
    Lu L; Li Z; Li H; Li X; Vekilov PG; Karniadakis GE
    Sci Adv; 2019 Aug; 5(8):eaax3905. PubMed ID: 31457104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of erythrocyte sickling by thiol reagents.
    Garel MC; Domenget C; Galacteros F; Martin-Caburi J; Beuzard Y
    Mol Pharmacol; 1984 Nov; 26(3):559-65. PubMed ID: 6493211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, Synthesis, and Biological Evaluation of Ester and Ether Derivatives of Antisickling Agent 5-HMF for the Treatment of Sickle Cell Disease.
    Xu GG; Pagare PP; Ghatge MS; Safo RP; Gazi A; Chen Q; David T; Alabbas AB; Musayev FN; Venitz J; Zhang Y; Safo MK; Abdulmalik O
    Mol Pharm; 2017 Oct; 14(10):3499-3511. PubMed ID: 28858508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The mechanism of action of two anti-sickling agents: sodium cyanate and glyceraldehyde.
    Manning JM; Acharya AS
    Am J Pediatr Hematol Oncol; 1984; 6(1):51-4. PubMed ID: 6711764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The sickling process in relation to clinical manifestations.
    Bellingham AJ
    J Clin Pathol Suppl (R Coll Pathol); 1974; 8():23-5. PubMed ID: 4536364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Viscosity and filtrability measurements of sickle-cell suspensions in the development of anti-sickling drugs.
    Ohnishi ST
    Blood Cells; 1982; 8(1):79-87. PubMed ID: 7115980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting HbS Polymerization.
    Ferrone FA
    Semin Hematol; 2018 Apr; 55(2):53-59. PubMed ID: 30616807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.